Related references
Note: Only part of the references are listed.KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma
Jason J. Luke et al.
FUTURE ONCOLOGY (2020)
Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival
Daniel C. Thomas et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Cutaneous Melanoma Version 2.2019
Daniel G. Coit et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma
Jennifer Keller et al.
CANCER MEDICINE (2019)
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients
Jonathan S. Zager et al.
BMC CANCER (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prediction of Residual Nodal Disease at Completion Dissection Following Positive Sentinel Lymph Node Biopsy for Melanoma
Andrew J. Sinnamon et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
NanoString, a novel digital color-coded barcode technology: current and future applications in molecular diagnostics
Hin-Fung Tsang et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2017)
Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013
Shoshana M. Landow et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma
Ahmad A. Tarhini et al.
MELANOMA RESEARCH (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence
Mari F. C. M. van den Hout et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Cost-Effectiveness of Nivolumab-lpilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States
Anna Oh et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2017)
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Jeffrey E. Gershenwald et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Margaret H. Veldman-Jones et al.
CANCER RESEARCH (2015)
Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy
Alisha Holtzhausen et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: Expert opinion
Axel Hauschild et al.
CANCER (2008)
Direct multiplexed measurement of gene expression with color-coded probe pairs
Gary K. Geiss et al.
NATURE BIOTECHNOLOGY (2008)
Tumour immunology - Tumour-induced immune modulation of sentinel lymph nodes
Alistair J. Cochran et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial
AMM Eggermont et al.
LANCET (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Gene expression profiling predicts clinical outcome of breast cancer
LJ van't Veer et al.
NATURE (2002)
Share Paper
